Literature DB >> 21718399

Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.

V Mirone1, A Sessa, F Giuliano, R Berges, M Kirby, I Moncada.   

Abstract

Benign prostatic hyperplasia (BPH) is a common disease in older men that can lead to lower urinary tract symptoms (LUTS). Male sexual dysfunction is also an age-related condition. Epidemiological studies have confirmed an association between BPH/LUTS and sexual dysfunction in ageing men that is independent of the effects of age, other co-morbidities and lifestyle factors. Proposed pathophysiological mechanisms for BPH/LUTS-associated sexual dysfunction include the nitric oxide/cyclic guanosine monophosphate (NO/cGMP) pathway, rho-kinase and endothelin-1 activity, autonomic nervous system overactivity and the metabolic syndrome, and pelvic organ atherosclerosis. Both BPH/LUTS and sexual dysfunction can have a substantial negative impact on a man's quality of life. However, urologists and primary care physicians appear to under-recognise sexual dysfunction in men with BPH/LUTS. Current guidelines recommend alpha-blockers and 5-alpha reductase inhibitors, either alone or in combination, among appropriate medical treatment options for BPH/LUTS. Randomised, controlled trials demonstrate that these therapies can be associated with sexual adverse effects (AEs) such as loss of libido, erectile dysfunction and ejaculatory disorders. Sexual dysfunction should be fully evaluated in men requiring treatment for BPH/LUTS using validated questionnaires. Management of sexual dysfunction in men treated for BPH/LUTS should involve assessment of co-morbidities and concomitant medications, consideration of lifestyle interventions such as weight loss and increased physical activity to improve risk factors and, if necessary, introduction of pharmacotherapies. In addition, physicians should provide patients with proper counselling on the possible sexual AEs of medical therapies for BPH/LUTS and their impact on sexual satisfaction, while being aware of the possibility that counselling in itself is likely to influence reported rates of sexual dysfunction.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21718399     DOI: 10.1111/j.1742-1241.2011.02731.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  13 in total

1.  Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?

Authors:  Li Tao Zhang; Jong Kwan Park
Journal:  World J Nephrol       Date:  2015-02-06

Review 2.  Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.

Authors:  Kalyan J Gangavarapu; Peter F Jowdy; Barbara A Foster; Wendy J Huss
Journal:  Am J Clin Exp Urol       Date:  2022-06-15

3.  Anti-proliferative, Anti-angiogenic and Anti-inflammatory Effects of Moringa peregrina Leaf Extracts on Testosterone- Induced Benign Prostatic Hyperplasia in Rats.

Authors:  Mazhar Salim Al Zoubi; Wesam Al Khateeb; Musab El-Oqlah; Mu'ath Migdady; Manl Issam Abu Al-Arja; Muna Bzour; Ahmad El-Oqlah; Samah Almubarak; Mahmoud A Al-Qudah; Khalid Al-Batayneh; Michella Mkhael; Ahmed Elokda; Prawej Ansari; Jma Hannan; Mohamed M Nasef; Murtaza M Tambuwala; Hamid A Bakshi
Journal:  Asian Pac J Cancer Prev       Date:  2022-01-01

4.  The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis.

Authors:  Shaun Wen Huey Lee; Esther Mei Ching Chan; Yin Key Lai
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

Review 5.  The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia.

Authors:  Jason Gandhi; Steven J Weissbart; Noel L Smith; Steven A Kaplan; Gautam Dagur; Anna Zumbo; Gargi Joshi; Sardar Ali Khan
Journal:  Transl Androl Urol       Date:  2017-04

6.  A survey of the FAERS database concerning the adverse event profiles of α1-adrenoreceptor blockers for lower urinary tract symptoms.

Authors:  Koji Yoshimura; Kaori Kadoyama; Toshiyuki Sakaeda; Yoshio Sugino; Osamu Ogawa; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-05-15       Impact factor: 3.738

Review 7.  Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review.

Authors:  Albert Haddad; Michel Jabbour; Muhammad Bulbul
Journal:  Arab J Urol       Date:  2015-07-10

8.  Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis.

Authors:  M Kirby; C Chapple; G Jackson; I Eardley; D Edwards; G Hackett; D Ralph; J Rees; M Speakman; J Spinks; K Wylie
Journal:  Int J Clin Pract       Date:  2013-04-25       Impact factor: 2.503

9.  Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies.

Authors:  Anita H Clayton; Suresh Durgam; Xiongwen Tang; Changzheng Chen; Adam Ruth; Carl Gommoll
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-21       Impact factor: 2.570

10.  Lower urinary tract symptoms and erectile dysfunction in men from the Republic of Moldova.

Authors:  I Dumbraveanu; E Ceban; P Banov
Journal:  J Med Life       Date:  2018 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.